Takeda, Andrea, Cooper, Keith, Bird, Alex, Baxter, Louise, Gospodarevskaya, Elena and Frampton, Geoffrey K.
Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
Health Technology Assessment
Full text not available from this repository.
Recombinant human growth hormone (somatropin) is currently recommended by NICE1 for children with a proven clinical diagnosis of GHD, TS or PWS and for pre-pubertal children with CRI. Since the last review, somatropin has received marketing authorisation for the treatment of children born SGA and for children with growth failure associated with SHOX deficiency. The review will update and extend the existing systematic review2 with any new evidence for the use of growth hormone for children with GHD, TS, PWS or CRI. In addition, evidence for the use of human growth hormone for children born small for gestational age, or with SHOX deficiency (conditions not considered in the original review) will be included in this report.
The HTA programme commissioned ths technology assessment report on behalf on the National Institute for Health and Clinical Excellence.
Actions (login required)